Shares of Evolus, Inc. (NASDAQ:EOLS - Get Free Report) hit a new 52-week low during trading on Tuesday . The company traded as low as $9.48 and last traded at $9.80, with a volume of 917290 shares trading hands. The stock had previously closed at $10.00.
Analysts Set New Price Targets
Several brokerages recently issued reports on EOLS. Cantor Fitzgerald reissued an "overweight" rating on shares of Evolus in a report on Monday, September 16th. HC Wainwright reiterated a "buy" rating and issued a $27.00 target price on shares of Evolus in a research note on Thursday, November 7th.
Read Our Latest Analysis on Evolus
Evolus Stock Down 5.0 %
The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The stock has a market capitalization of $589.52 million, a P/E ratio of -10.23 and a beta of 1.32. The stock's fifty day moving average is $12.11 and its two-hundred day moving average is $13.75.
Institutional Trading of Evolus
A number of hedge funds have recently bought and sold shares of EOLS. Quest Partners LLC purchased a new position in shares of Evolus during the 2nd quarter valued at $43,000. Quarry LP bought a new position in Evolus during the second quarter valued at approximately $54,000. Profund Advisors LLC bought a new stake in Evolus in the second quarter worth approximately $130,000. Point72 Asset Management L.P. acquired a new position in shares of Evolus during the 3rd quarter worth $132,000. Finally, Arizona State Retirement System raised its holdings in shares of Evolus by 9.4% during the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company's stock valued at $158,000 after purchasing an additional 1,253 shares in the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.
About Evolus
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Articles
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
